European Association of Urology Guidelines on Renal Cell Carcinoma : The 2019 Update
(2019) In European Urology 75(5). p.799-810- Abstract
Context: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. Objective: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable. Evidence acquisition: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries,... (More)
Context: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. Objective: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable. Evidence acquisition: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework. Evidence synthesis: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence. Conclusions: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019. Patient summary: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.
(Less)
- author
- organization
- publishing date
- 2019-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Diagnosis, European Association of Urology, Follow-up, Guidelines, Management, Medical, Renal cell cancer, Surgery
- in
- European Urology
- volume
- 75
- issue
- 5
- pages
- 12 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85061841950
- pmid:30803729
- ISSN
- 0302-2838
- DOI
- 10.1016/j.eururo.2019.02.011
- language
- English
- LU publication?
- yes
- id
- 7ffaf4d4-4708-498a-87b4-e87dfb76573a
- date added to LUP
- 2019-03-04 13:49:06
- date last changed
- 2024-04-16 00:48:36
@article{7ffaf4d4-4708-498a-87b4-e87dfb76573a,
abstract = {{<p>Context: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. Objective: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable. Evidence acquisition: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework. Evidence synthesis: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence. Conclusions: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019. Patient summary: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.</p>}},
author = {{Ljungberg, Börje and Albiges, Laurance and Abu-Ghanem, Yasmin and Bensalah, Karim and Dabestani, Saeed and Montes, Sergio Fernández Pello and Giles, Rachel H. and Hofmann, Fabian and Hora, Milan and Kuczyk, Markus A. and Kuusk, Teele and Lam, Thomas B. and Marconi, Lorenzo and Merseburger, Axel S. and Powles, Thomas and Staehler, Michael and Tahbaz, Rana and Volpe, Alessandro and Bex, Axel}},
issn = {{0302-2838}},
keywords = {{Diagnosis; European Association of Urology; Follow-up; Guidelines; Management; Medical; Renal cell cancer; Surgery}},
language = {{eng}},
number = {{5}},
pages = {{799--810}},
publisher = {{Elsevier}},
series = {{European Urology}},
title = {{European Association of Urology Guidelines on Renal Cell Carcinoma : The 2019 Update}},
url = {{http://dx.doi.org/10.1016/j.eururo.2019.02.011}},
doi = {{10.1016/j.eururo.2019.02.011}},
volume = {{75}},
year = {{2019}},
}